Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
(NASDAQ: ACXP) Delayed: 1.51 -0.03 (1.95%)
Previous Close $1.54    52 Week High $ 
Open $1.59    52 Week Low $ 
Day High $1.59    P/E N/A 
Day Low $1.51    EPS $ 
Volume 80,832